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Objective: To identify the frequencies (F) of ferredoxin and nitroreductase mutations
on Iranian clinical isolates of Giardia lamblia in order to predict whether the nita-
zoxanide can be prescribed as suitable drug for symptomatic to metronidazole-resistant
giardiasis.
Methods: Forty Giardia lamblia isolates as of 38 symptomatic and two metronidazole-
resistant patients were collected from Iran. DNAs were extracted and ampliﬁed by tar-
geting ferredoxin and GlNR genes. The amplicons were directly sequenced to determine
gene mutations.
Results: The various amino acid substitutions (F: 20%, Haplotype diversity: 0.891,
Tajima's D: −0.44013) were identiﬁed by analyzing ferredoxin gene in four symptomatic
and two resistant isolates. Only two haplotypes (F: 5%, HD: 0.345; Tajima's D: 0.77815)
characterized in metronidazole-resistant isolates of GlNR, however, no point mutations
was found in symptomatic isolates.
Conclusions: Non-synonymous mutations of ferredoxin oxidoreductase gene reduce
translational regulatory protein's binding afﬁnity which concludes reduction of ferredoxin
expression and its activity. This leads to decrease in metronidazole drug delivery into the
cells. Mutations in these isolates may lead to their resistance to metronidazole. No to low
synonymous mutations of GlNR demonstrates that nitazoxanide can be prescribed as
promising alternative treatment for symptomatic to metronidazole-resistant giardiasis in
Iranian clinical isolates.1. Introduction
Giardia lamblia (G. lamblia) (syn. Giardia intestinalis or
Giardia duodenalis) as a microaerophilic gastrointestinal
parasitic protest is a causative agent of steatorrhea affecting
one billion people worldwide with annual incidence of (200–
300) million cases [1,2]. Approximately, 15% of Giardia
infections are explicitly occur among children (0–24) months
in the developing countries [3] and contributes to the second-
leading cause of death in children under ﬁve years old [4,5].Based on type of parasitic assemblage and its sensitivity/
resistance to treatment, giardiasis may be manifested to
chronic and acute symptoms including nausea, diarrhea,
vomiting, bloating, dehydration, malabsorption syndrome and
failure to thrive [1]. On the one hand G. lamblia has been
also attributed in the etiology of type II diabetes, obesity and
irritable bowel syndrome [6,7]. Giardiasis treatment is
currently restricted to nitroheterocyclic (Metronidazole;
efﬁcacy 73%–100%, nitazoxanide and furazolidone) and
benzimidazoles (Albendazole; efﬁcacy 79%–100% and
mebendazole) compounds [8,9]. A number of drugs such as
paromomycin and quinacrine because of their low efﬁcacy
and high toxicity are infrequently prescribed [8]. However,
one of the global difﬁculties (particularly in Iranian clinical
isolates) concerning ﬁrst line treatment of G. lamblia isder the CC BY-NC-ND license (http://
Figure 1. The stained Giardia lamblia cyst by trichrome staining (1000×
magniﬁcation).
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clinical isolates. The inactive form (oxide) of metronidazole
enters the cell through passive diffusion into G. lamblia and
is reduced by pyruvate-ferredoxin oxidoreductase (PFOR) in
mitochondria organelle and nitrogen is converted to toxic
radicals [10,11]. Ferredoxin oxidoreductase gene mutations of
G. lamblia can reduce translational regulatory protein's
binding afﬁnity which leads to reduction of ferredoxin
expression and its resistance to metronidazole. However, it is
not easy to distinguish between cure followed by re-infection
or other disorders such as lactose intolerance. A number of
studies have been evaluated resistance to differential regulation
of oxidoreductase enzymes in mRNA expression levels on
nitroheterocyclic resistance laboratory lines (WB, 106, and 713
isolates) [12–19], however, no comprehensive study has
conducted on nitroheterocyclic resistance of clinical isolates
of G. lamblia in replication (DNA) level yet. One of the
major problems in treatment of metronidazole-resistant clin-
ical isolates is attributed to metronidazole permeability that
does not affect on the respiration of encysting trophozoites and
mature cysts, also it do not has signiﬁcant changes in cyst
production at lower concentrations [20]. On the other hand, the
numerous side effects of metronidazole have been extensively
proven among users. Therefore, using an effectual alternative
drug with more cytotoxic activity on both trophozoites and
mature cysts and lowest adverse effects should be noticed
[21]. In 2004, the nitrothiazolide nitazoxanide (Alinia) as an
alternative option has been approved for the pediatric
treatment of giardiasis in the USA [22]. This drug
compromises the integrity of the cell by causing lesions in
the ventral cell membrane and inducing vacuolization [22].
G. lamblia nitroreductase (GlNR) has known as a
nitazoxanide-binding protein in drug resistance. In this study,
the frequencies (F) of ferredoxin and nitroreductase mutations
were identiﬁed on Iranian clinical isolates of G. lamblia in
order to predict whether the nitazoxanide can be prescribed as
suitable treatment for symptomatic to metronidazole-resistant
giardiasis.2. Material and methods
2.1. Sampling, cyst puriﬁcation and DNA extraction
During Feb 2014–March 2015, forty Giardia positive-
microscopic human fecal samples were collected from north-
west Iran (East Azerbaijan and Ardabil provinces). A total of
38 patients had various range of symptoms including nausea,
bloating, dehydration and steatorrhea (fatty diarrhea). Also,
based on tracking of clinical and microscopic investigations,
two patients did not have any effective treatment to metroni-
dazole in one last year. The collected specimens were pre-
served in 70% ethanol and stored at 4 C until molecular
analysis. Specimens, especially cysts, were puriﬁed and
concentrated by ﬂotation on sucrose with speciﬁc gravity of
0.85 M. The puriﬁed cyst was stained by trichrome staining
(Figure 1). The genomic DNA of G. lamblia isolates was
extracted through the freeze-thawing technique [10 cycles of
freezing (10 min at liquid nitrogen) and thawing (10 min at
95 C)]. Also, 200 mL of Giardia cyst suspension were com-
bined with an equal volume of glass beads followed byvortexing for (8–10) min. After adding 30 mL of proteinase K,
the suspension was incubated at 60 C for one overnight. DNA
extraction was done using Stool DNA Isolation mini kit (Yekta
Tajhiz Azma, Iran) following the manufacturer's instructions
with some modiﬁcations. All extracted DNA was stored
at −20 C.2.2. Primer designing and PCR ampliﬁcation
Given that the earlier used primers had a short length in
order to identify unknown mutations (haplotypes), the target
primers of PFOR and G1NR genes were designed by Oligo
Analyzer 3.1 tool based on reference accession numbers of
XM_001707879.1 (NR) and L27221 (PFOR). In the PCR re-
action, ferredoxin gene was ampliﬁed using the forward primer
(PFOR-F) 50-GCCAGCTCCTTCTTGTCTT-30 and the reverse
primer (PFOR-R) 50-CACGACGATCAGGTCTCTCG-30.
Also, G1NR gene was ampliﬁed using the forward primer (NR-
F) 50-CGAGACAAAGGTAGTGGCGT-30 and the reverse
primer (NR-R) 50-GCCACAGCAGCTAAGAGGAA-30. The
efﬁcacy of the designed primers was tested by standard positive
control. The PCR ampliﬁcation was carried out in 25 mL re-
action volumes containing 0.3 mL (5 U/mL) of Taq DNA po-
lymerase (Cinnagen, Iran), 2.5 mL of 10× PCR buffer
(Cinnagen, Iran), 0.9 mL (50 mM) MgCl2 (Cinnagen, Iran),
0.5 mL (10 mM) of dNTP Mix (Cinnagen, Iran), (10–13) mL
deionized distilled water, 1 mL of each forward and reverse
primers (10 pmol), (3–4) mL of bovine serum albumin 0.1% as
enhancer, and 4 mL of DNA template. Reactions were per-
formed in a thermal cycler PCR System (Eppendorf-Germany).
The thermal cycling protocol for both PFOR and GlNR genes
included an initial cycle of 95 C for 10 min, followed by 40
cycles of 94 C for 30 s, 60 C for 45 s, 72 C for 1 min and a
ﬁnal extension of 72 C for 10 min. The PCR products were
electrophoresized on 1% (W/V) agarose gel stained with DNA
safe stain.
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The all amplicons of PFOR and G1NR genes were puriﬁed
using Gel Puriﬁcation Kit (BiONEER, South Korea) according
to manufacturer's instructions. The ﬁnal DNA concentration was
estimated by comparing with DNA Ladder Marker (Promega) in
1.5% agarose gel. Amplicons were directly sequenced by tar-
geting ferredoxin and GlNR genes by ABIPRISMTM 3130
Genetic Analyzer automated sequencer (Applied Biosystems,
USA). Ambiguous sites were coded using the standard IUPAC
codes for combinations of two or more bases. Contigs (over-
lapped sequences) of all samples were aligned and edited visu-
ally at consensus positions compared to GenBank sequences
using Sequencher™ v.4.1.4 and BioEdit softwares [23]. The
number of novel haplotypes, diversity indices (Haplotype
diversity; Hd and Nucleotide diversity: p) and neutrality
indices (Tajima's D and Fu's Fs tests) were estimated by
DnaSP software version 5.10 [24]. A haplotype network based
on mitochondrial concatenate sequences of PFOR and GlNR
genes was drawn by PopART software in order to distribute
identiﬁed haplotypes [25]. Also, the phylogenetic tree was
constructed by MEGA 5.05 software based on maximum
likelihood algorithm and circle model to show topology of
distinct isolates compared to same isolates [26]. The accuracy
of phylogenetic tree was evaluated by 1000 bootstrap re-
sampling.Figure 2. Agarose gel electrophoresis of PCR products.
A: PF1-PF7: G. lamblia isolates ampliﬁed based on ferredoxin gene (PF).
B: NR1-NR7: G. lamblia isolates ampliﬁed based on Nitroreductase gene
(NR) +Ve: Positive control, −Ve: Negative control, M: 100 bp DNA size
marker.
Figure 3. A haplotype network according on mitochondrial concatenate
sequences of ferredoxin and GlNR genes in metronidazole resistant Giardia
isolates (PFOR2, 3 and NR2, 3) and symptomatic specimens.3. Results
The PFOR (nearly 980 bp) and GlNR (nearly 552 bp)
genes were successfully ampliﬁed from all 40 isolates
(Figure 2). Only two haplotypes NR2 (accession number;
KX181723) and NR3 (accession number; KX181724)
(Transition model; Cytosin converted to thymine, F: 5%)
were identiﬁed in metronidazole resistant isolates of GlNR
(Figure 3) whilst, no point mutations was found in symp-
tomatic isolates. Eight novel haplotypes (F: 20%) were
identiﬁed by analyzing ferredoxin gene which among of
them, two (PFOR2: accession no: KX181715 and PFOR3:
KX181716) and six (PFOR4-PFOR9: accession nos:
KX181717-KX181722) haplotypes were belonged to resistant
and symptomatic isolates respectively (Figure 3). Various
amino acid substitutions were characterized at different co-
dons (76, 97, 116, 134, 172, 224, 238, 245, 248, 250 and
276) of resistant isolates (PFOR2 and PFOR3). Moreover,
amino acid replacement identiﬁed at various codons (28, 29,
76, 97, 99, 116, 134, 172, 245, 250 and 276) of some
symptomatic isolates (PFOR4, 5, 8 and 9) (Figure 4). How-
ever, no new mutation (haplotypes) was found in the rest
sequences of ferredoxin gene compared to wild type (PFOR1,
Ref L27221). According to the analysis of molecular variance
(AMOVA) test, the high Hd value of ferredoxin (0.891) was
shown the principal pattern of the total genetic variability
within Giardia populations whilst nucleotide diversity was
low in both genes (p; 0.00093 to 0.00679) (Table 1). Unlike
GlNR gene, the neutrality indices of the ferredoxin oxidore-
ductase were shown negative values (−0.44013 for Tajima'sD to −1.046 for Fu's Fs statistic) (Table 1). The status of
metronidazole-resistant isolates and other sequences were
shown in Figure 5 which isolates PFOR2, 3, 8, 9 and NR2, 3
have placed in distinct branches.
Table 1
Diversity and neutrality indices of Giardia lamblia based on nucleotide sequences of Pyruvate ferredoxin oxidoreductase and Nitroreductase genes.
Gene Diversity indices Neutrality indices
N Hn Hd ± SD Nd (p) ± SD Tajima's D Fu's Fs statistic
PFOR 40 8 0.891 ± 0.092 0.00679 ± 0.00173 −0.44013 −1.046
NR 40 2 0.345 ± 0.172 0.00093 ± 0.00088 0.77815 0.659
Hn: number of haplotypes; Hd: haplotype diversity; Nd: nucleotide diversity.
Figure 5. Phylogenetic tree of G. lamblia ferredoxin oxidoreductase and GlNR sequences in metronidazole resistant isolates (PFOR2, 3 and NR2, 3) and
symptomatic specimens using maximum likelihood algorithm with kimura 2-parameter model and 1000 bootstrap re-sampling.
Figure 4. Comparison of protein sequences of ferredoxin oxidoreductase gene of G. lamblia in metronidazole resistant isolates (PFOR2**, PFOR3**) and
symptomatic specimens compared to wild type (PFOR1).
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In this investigation, for the ﬁrst time the various ranges of
PFOR and GlNR mutations were ampliﬁed and identiﬁed in
symptomatic to metronidazole resistant Iranian clinical isolates
of G. lamblia by sequencing and AMOVA analysis. The
mechanisms of metronidazole resistance have been extensively
negotiated during the last 40 years, although the approaches are
often contradictory to put into viewpoint.
The majority clinical investigations on chemotherapy of
giardiasis reveal that, despite the drug used, cure rates are below
100%. Apart from drug refractory, other predisposing factors
can also be accountable for treatment failure, covering seques-
tration of parasite in the gallbladder or the pancreas, re-infection,
inadequate amounts of drug administered and immune deﬁ-
ciency [27].
It is noteworthy that G. lamblia isolated from patients with
resistant giardiasis do not regularly show drug resistance in vitro
[28]. It can be justiﬁed by some immune-physiological inﬂuences
of the human host on the success of a given chemotherapy.
Several studies have been shown a strong association be-
tween down regulation of PFOR gene and drug resistance on
cell lines (in vitro), bacteria and Trichomonas vaginalis in
translation and mRNA expression levels [17,29–31]. Reduction of
ferredoxin oxidoreductase translation in resistant strains
enhances this assumption that by the decrease of the cells'
ability to regenerate metronidazole into cytotoxic free radicals.
In addition, it is hypothesized that mutations of ferredoxin
gene reduce the activity of PFOR. However, there is no
associated study between correlation of ferredoxin mutation
and drug resistance on clinical isolates of G. lamblia in
replication level.
In this study, 20% mutant strains of ferredoxin gene con-
taining various codon substitution and high haplotype diversity
(0.891) was unequivocally identiﬁed among all resistant isolates
(n = 2) and six symptomatic specimens. This fact can be
described by non-synonymous mutations of ferredoxin reduce
translational regulatory protein's binding afﬁnity which
conclude reduction of ferredoxin expression and its activity.
This leads to decrease in metronidazole drug delivery into the
cells. Mutations in these isolates may lead to resistance of them
to metronidazole.
On the other hand, 5% mutant strains of GlNR gene without
any codon substitution and low haplotype diversity (0.345) was
only recognized in resistant isolates (n = 2). This no to low
synonymous mutations of GlNR exhibits that nitazoxanide can
be potentially used as an alternative treatment in symptomatic to
metronidazole-resistant Iranian clinical isolates. Unlike metro-
nidazole drug, so far no evidence has been found for any tera-
togenic or mutagenic activity of nitazoxanide, in addition the last
drug has more effectual cytotoxic activity on trophozoites and
mature cysts in encystations process [8,22].
Up to now, nitazoxanide resistance has been merely observed
in the laboratory [16]. In a study, a nitazoxanide-resistant cell line
was robustly resistant to metronidazole, while a cell line with
induced metronidazole resistance was susceptible to nitazox-
anide [16]. In consistent with our ﬁndings, this indicates that
cross resistance between both drugs is not essentially
reciprocal. In a study on the nitazoxanide resistant cell line
illustrated chaperone proteins Hsp 70 and Hsp 90 to be up-
regulated in expression [17]. Several research papers have
been revealed that NR1 and NR2 have crucial role in themetabolism of metronidazole in G. lamblia. Down-regulation
of NR1 is lead to metronidazole-resistant laboratory cell line
whereas NR2 was found to be up-regulated in metronidazole-
resistant [18,21].
In conclusion, we showed that a high frequency range of
ferredoxin mutations including amino acids/haplotypes are
unambiguously circulating among resistant metronidazole pa-
tients and some symptomatic giardiasis in Iran. This is an alert
that a number of symptomatic specimens are potentially con-
verting to resistant isolates. No to low synonymous mutations of
GlNR demonstrates that nitazoxanide as promising alternative
drug can be prescribed to treatment symptomatic to
metronidazole-resistant Iranian clinical isolates. Taken together,
although treatment failures and drug resistance in Giardia can be
problematic, but hopeful novel drugs and combination therapy
may be affected in promising treatment strategies.Conﬂicts of interest statement
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